Another study suggested that the role of ATG4B in prostate cancer is cell type-, treatment-, and context-dependent [97], showing that the use of a dominant negative construct can either enhance the effect of chemotherapy or contribute to treatment resistance. Here, ATG4B is linked to prostate cancer.